Accessibility StatementSkip Navigation ADC Platforms Keynote speech R&D Strategy "Over the past decade, Innovent has been at the forefront of China's biopharmaceutical evolution—pioneering the PD-1 immunotherapy era and building China's leading oncology brand, with over 3 million cancer patients treated with our therapies," said Dr. Michael Yu, Founder, Chairman of the Board and CEO of Innovent. "We are entering a new chapter focused on global innovation, powered by a robust pipeline and dual innov ...

Global Research Highlights Halftime Report & All Things "AI" Investment Strategy Resilient growth in a precarious world As we close out the first half of the year, BofA's Head of Global Econ, Claudio Irigoyen, upgrades our 2025 global growth forecast by 20bp, largely explained by China benefiting from the trade truce. We expect the global economy to grow 3% in 2025 and 2026, accelerating to 3.3% in 2027. We forecast global inflation to hover around 2.5% as economies absorb the tariffs shock. While trade de- ...

Core Viewpoint - A lawsuit has been filed against Organon & Co. and its senior executives for potential violations of federal securities laws, particularly related to misleading statements about dividend policies following a significant acquisition [1][2][3]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the District of New Jersey, titled Hauser v. Organon & Co., et al., No. 25-cv-05322, and claims are made under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [2]. - Investors have until July 22, 2025, to request to lead the case [2]. Group 2: Company Background and Acquisition - Organon is a global healthcare company focused on women's health, known for rewarding shareholders with dividends [3]. - In October 2024, Organon completed a $1.2 billion acquisition of Dermavant, a biopharmaceutical company, which increased its debt [3]. Group 3: Dividend Policy and Stock Performance - Following the acquisition, Organon assured investors it would maintain its dividend, which was stated as its "1 capital allocation priority" [3]. - However, the company later shifted its focus to debt reduction, leading to a significant cut in its dividend from $0.28 per share to $0.02 per share on May 1, 2025 [4]. - This announcement resulted in a 27% decline in Organon's stock price, dropping from $12.93 per share on April 30, 2025, to $9.45 per share on May 1, 2025 [4].

Core Viewpoint - A lawsuit has been filed against Iovance Biotherapeutics, Inc. and certain senior executives for potential violations of federal securities laws, specifically related to the company's performance and treatment timelines for its melanoma drug Amtagvi [1][2]. Company Overview - Iovance Biotherapeutics is a commercial-stage biopharmaceutical company focused on developing treatments for melanoma and other solid tumor cancers [3]. Product Launch and Performance - Iovance launched its key melanoma treatment, Amtagvi, in February 2024, administering it at authorized treatment centers (ATCs) [3]. - The company has faced challenges with ATCs, including long timelines for patient treatment initiation and ineffective patient identification, leading to high patient drop-off rates [4]. Financial Impact - On May 8, 2025, Iovance reported disappointing financial results for the first quarter of 2025 and revised its full-year 2025 revenue guidance downward, citing slow treatment timelines and high patient drop-off rates as contributing factors [5]. - Following the announcement of poor financial results, Iovance's stock price fell over 44%, from $3.17 per share to $1.75 per share within a day [6].

Core Insights - Arcutis Biotherapeutics has received FDA approval for its product ZORYVE, a PDE4 inhibitor, which expands the drug's existing label [1] - The company focuses on small and microcap biopharmaceuticals, where mispricing is most intense and institutional attention is limited [1] - The analyst team consists mainly of high-ranking Life Sciences students from top UK universities, aiming to improve the accuracy of clinical stage equity research [1] Company Overview - ZORYVE is positioned favorably among physicians due to its mechanism of action as a PDE4 inhibitor [1] - The company targets young, often clinical stage biopharmaceutical firms that typically lack institutional coverage [1] Market Dynamics - Retail investors make up the majority of public ownership in these small biopharmaceutical companies, leading to price movements that may not reflect material information [1] - Analyst coverage from investment banks often results in significant market movements, despite potential conflicts of interest [1]

Core Viewpoint - Quantum BioPharma Ltd. is completing a non-brokered private placement of class A multiple voting shares at a price of $50 per share, aiming for gross proceeds of up to $600 million, expected to be fully subscribed by existing holders of MVS [1][3]. Group 1: Offering Details - The Offering consists of class A multiple voting shares priced at $50 each, with total gross proceeds anticipated to reach $600 million [1]. - All securities issued in the Offering are subject to a statutory hold period of four months plus a day from issuance, in accordance with Canadian securities laws [2]. - The proceeds from the Offering will be utilized for general working capital purposes [2]. Group 2: Insider Participation - The Offering is expected to be fully subscribed by Xorax Family Trust and Fortius Research and Trading Corp., both of which have insider connections to the Company [3]. - The participation of these insiders is classified as a "related-party transaction" under Multilateral Instrument 61-101, with exemptions from formal valuation and minority shareholder approval requirements being relied upon [3]. Group 3: Company Overview - Quantum BioPharma is focused on developing innovative biopharmaceutical solutions for neurodegenerative and metabolic disorders, with drug candidates at various development stages [6]. - The Company’s lead compound, Lucid-MS, is designed to prevent and reverse myelin degradation, a key factor in multiple sclerosis, and is currently in preclinical models [6]. - Quantum BioPharma retains a 20.11% ownership stake in Unbuzzd Wellness Inc. and is entitled to royalty payments of 7% on sales until reaching $250 million, after which the royalty rate will decrease to 3% [6].

Bexotegrast development in IPF discontinued Clinical oncology program and early-stage programs continue Recent workforce and operational changes align with next steps SOUTH SAN FRANCISCO, Calif., June 27, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced that following the review of data from the recently terminated BEACON-IPF Phase 2b/3 clinical trial, the Company has discontinued development of bexotegrast in idiopathic pulmonary fibrosis (IPF). BEACON-IPF Trial Update BEA ...

Core Points - Xenon Pharmaceuticals Inc. has been added to the Russell 3000® and Russell 2000® Indexes as part of the annual reconstitution effective June 27, 2025 [1] - The Russell 3000® Index tracks the performance of the largest 3,000 U.S. stocks by market capitalization, while the Russell 2000® Index measures the performance of the 2,000 smallest companies within the Russell 3000® Index [2] - Approximately $10.6 trillion in assets are benchmarked against Russell U.S. indexes, making them widely used by investment managers and institutional investors [3] Company Overview - Xenon Pharmaceuticals is a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics [4] - The company is advancing an ion channel product portfolio to address high unmet medical needs, including epilepsy and depression [4] - Azetukalner, a novel and highly potent selective Kv7 potassium channel opener, is the most advanced clinically validated potassium channel modulator in late-stage clinical development for multiple indications [4]

STOCKHOLM, SWEDEN June 27, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company, Modus Therapeutics carries out a fully secured rights issue of units of SEK 28.3 million. The proceeds from the rights issue are intended to finance the continued development of the drug candidate sevuparin in chronic kidney disease with anemia. On June 26 2025, the portfolio company Modus Therapeutics, listed on Nasdaq First North Growth Market, announced that the company is carry ...

Core Insights - Neurocrine Biosciences announced significant reductions in cognitive and motor-related burdens in adults with Huntington's disease chorea treated with INGREZZA (valbenazine) capsules, based on new patient-reported post-hoc data from the KINECT-HD study [1][4] Group 1: Study Findings - The KINECT-HD study is the first clinical trial to show measurable changes in cognitive and motor disease burden with a vesicular monoamine transporter 2 inhibitor in Huntington's disease patients [1][2] - In the 12-week Phase 3 KINECT-HD clinical trial, INGREZZA showed a significant reduction in chorea severity, with a placebo-adjusted mean reduction in the Total Maximal Chorea (TMC) score of 3.2 units (p<0.0001) [11] - Patient-reported analyses indicated greater reductions in cognitive and motor-related disease burden for INGREZZA compared to placebo across various domains, including memory loss and mobility limitations [3][4] Group 2: Cognitive and Motor-Related Improvements - Statistically significant improvements were observed in cognition-related items, such as memory loss (-0.9 for INGREZZA vs -0.2 for placebo) and decision-making abilities (-1.0 for INGREZZA vs -0.3 for placebo) [3] - For motor-related items, INGREZZA demonstrated larger reductions in scores compared to placebo, including abnormal movements (-1.5 for INGREZZA vs -0.8 for placebo) and impaired coordination (-1.0 for INGREZZA vs -0.4 for placebo) [3][5] Group 3: Background on Huntington's Disease - Huntington's disease is a hereditary progressive neurodegenerative disorder affecting approximately 41,000 adults in the U.S., characterized by motor, cognitive, and psychiatric symptoms [7] - Chorea, a common symptom of Huntington's disease, involves irregular and unpredictable movements that can interfere with motor coordination and daily activities [7] Group 4: About INGREZZA - INGREZZA is a selective vesicular monoamine transporter 2 (VMAT2) inhibitor approved for treating chorea associated with Huntington's disease and tardive dyskinesia [14][15] - The drug is designed for once-daily administration without the need for titration, making it convenient for patients [16]